2025-12-19 - Analysis Report
Okay, let's break down the analysis of Teladoc Health Inc. (TDOC).

**1) Return Rate Comparison**

*   **Company Overview:** Teladoc Health Inc. is a telehealth and virtual healthcare company.
*   **TDOC Cumulative Return:** -64.70%
*   **VOO (S&P 500) Cumulative Return:** 100.13%
*   **Divergence:** -164.83
*   **Relative Divergence:** 0.5

**Analysis:**

TDOC has significantly underperformed the S&P 500 (VOO) over the specified period. The divergence is a substantial -164.83%. The relative divergence of 0.5 suggests that the current divergence is near the lower end of its historical range (very close to the minimum divergence observed). This indicates that the underperformance *relative* to the S&P 500 is as bad as it has been in the analyzed period.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD   | Alpha   | Beta   | Cap(B) |
|------------|--------|-------|---------|--------|--------|
| 2015-2017  | 77.0%  | 70.4% | 51.0%   | -0.1  | 6.2    |
| 2016-2018  | 101.0% | 69.4% | 86.0%   | -0.1  | 8.8    |
| 2017-2019  | 141.0% | 73.8% | 118.0%  | 0.3   | 14.9   |
| 2018-2020  | 105.0% | 80.9% | 81.0%   | 0.3   | 35.5   |
| 2019-2021  | -78.0% | 80.9% | -125.0% | 0.3   | 16.3   |
| 2020-2022  | -252.0% | 85.9% | -251.0% | -0.9  | 4.2    |
| 2021-2023  | -315.0% | 85.9% | -316.0% | -1.8  | 3.8    |
| 2022-2024  | -93.0% | 85.9% | -113.0% | -1.9  | 1.6    |
| 2023-2025  | -36.0% | 81.6% | -99.0%  | -0.8  | 1.3    |

**Analysis:**

*   **CAGR:** Shows a dramatic decline in annual growth rates, shifting from triple-digit gains to significant losses.
*   **MDD:** Consistently high Maximum Drawdown figures indicate substantial risk and volatility.
*   **Alpha:** The Alpha values are overwhelmingly negative in recent years, indicating significant underperformance compared to the benchmark.  Alpha went from positive to negative.
*   **Beta:** The Beta values shift from positive to increasingly negative territory, suggesting that TDOC has become negatively correlated with the market in more recent years. This means it tends to move in the *opposite* direction of the market.
*   **Cap(B):** The market capitalization has shrunk significantly in recent years.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 7.14
*   **Previous Close:** 7.25
*   **Change:** -1.52%
*   **5-day SMA:** 7.338
*   **20-day SMA:** 7.42
*   **60-day SMA:** 7.9174

**Analysis:**

The stock is trading below all three moving averages (5, 20, and 60-day), indicating a short-term downtrend. The negative change from the previous close (-1.52%) reinforces this bearish sentiment.

**3) Indicators Analysis**

*   **MRI:** 0.7 (Medium Investment)
*   **RSI:** 33.21 (Approaching Oversold)
*   **PPO:** -0.1144 (Negative)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (132 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change:** 0.0 (short-term decline)
*   **Expected Return:** -10274.4%

**Analysis:**

*   The MRI suggests a medium investment risk based on the model.
*   The RSI value of 33.21 is approaching the oversold territory (typically below 30), which *could* suggest a potential for a rebound.  However, oversold conditions can persist for extended periods in a strong downtrend.
*   The negative PPO confirms the downtrend.
*   Recent (20 days) relative divergence change = 0.0 (-): short-term decline.
*   The Hybrid Signal provides a specific investment strategy, advocating for a 100% cash allocation to buying 132 shares, with monthly investments, categorized as "Very Safe" with a high MRI score.
*   The extremely negative expected return (-10274.4%) is a major red flag, suggesting significant potential losses if holding the stock long-term.

**4) Recent News & Significant Events**

*   **[2025-11-25]** Assessing Valuation After Recent Short-Term Share Price Rebound - Implies some recent positive movement, but still focuses on valuation.
*   **[2025-12-18]** Receives Consensus Rating of "Hold" from Brokerages - A neutral outlook.
*   **[2025-12-18]** Responsive Playbooks and the TDOC Inflection - Suggests a potential turning point, but needs further investigation.
*   **[2025-12-17]** Reassessing Valuation After New $13.6 Million ESOP Shelf Registration Filing - Focus on valuation, with ESOP shelf registration hinting at potential dilution.
*   **[2025-12-03 & 2025-12-04]** Insider Sale: President of BetterHelp sells shares -  Insider selling can be a negative signal.

**Analysis:**

The news is mixed. While some articles suggest a potential turning point or a recent rebound, others focus on valuation concerns and insider selling. The consensus "Hold" rating reflects this uncertainty. The ESOP shelf registration could dilute shareholder value.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.67 (Hold)
*   **Number of Opinions:** 22
*   **Target Price (avg/high/low):** 9.18 / 12.00 / 7.00

**Analysis:**

The analyst consensus is "Hold," with a mean rating of 2.67. The average target price of $9.18 suggests a potential upside from the current price, but the low target of $7.00 indicates some analysts see further downside risk. The recent rating changes are not provided in the data.

**5) Recent Earnings Analysis**

| Date       | EPS   | Revenue    |
|------------|-------|------------|
| 2025-10-30 | -0.28 | 0.63 B$    |
| 2025-07-30 | -0.19 | 0.63 B$    |
| 2025-05-01 | -0.53 | 0.63 B$    |
| 2024-10-31 | -0.19 | 0.64 B$    |
| 2025-10-30 | -0.19 | 0.64 B$    |

**Analysis:**

*   EPS remains negative, indicating a lack of profitability. The loss per share is fluctuating.
*   Revenue is relatively stable around $0.63-0.64 billion per quarter.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30   | $0.63B     | 70.12%          |
| 2025-06-30   | $0.63B     | 69.85%          |
| 2025-03-31   | $0.63B     | 68.73%          |
| 2024-12-31   | $0.64B     | 70.50%          |
| 2024-09-30   | $0.64B     | 71.94%          |

**Analysis:**

*   Revenue is consistent.
*   Profit margin is healthy (around 70%) but shows a slight decreasing trend.

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $1.39B     | -3.56%  |
| 2025-06-30   | $1.42B     | -2.30%  |
| 2025-03-31   | $1.43B     | -6.52%  |
| 2024-12-31   | $1.49B     | -3.25%  |
| 2024-09-30   | $1.51B     | -2.21%  |

**Analysis:**

*   Equity is decreasing, indicating a shrinking book value.
*   ROE is negative, confirming the lack of profitability and poor return on shareholder equity. The ROE fluctuation indicates instability.

**7) Comprehensive Analysis**

Teladoc Health Inc. (TDOC) presents a concerning picture based on the provided data.

*   **Underperformance:** The stock has significantly underperformed the S&P 500.
*   **Downtrend:** Technical indicators (SMA, PPO) suggest a continuing downtrend.
*   **Negative Profitability:** EPS and ROE are consistently negative.
*   **Decreasing Equity:** Shareholder equity is declining.
*   **Mixed Sentiment:** News and analyst opinions are mixed, with some signs of potential recovery but persistent valuation concerns.
*   **Insider Selling:** Recent insider selling is a potentially negative signal.
*   **High Risk:** The negative expected return and high MDD indicate substantial risk.

**Conclusion:**

Based on the information available, investing in TDOC at this time appears highly risky. While the stock might be approaching oversold conditions and analysts see some potential upside, the fundamental issues of negative profitability, declining equity, and significant underperformance, coupled with the mixed news sentiment, warrant extreme caution. The extremely negative expected return is particularly alarming.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.